Industry
Biotechnology
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
Loading...
Open
1.94
Mkt cap
91M
Volume
250K
High
1.94
P/E Ratio
-0.59
52-wk high
20.22
Low
1.83
Div yield
N/A
52-wk low
1.55
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 12:14 pm
Portfolio Pulse from Benzinga Newsdesk
August 09, 2024 | 5:57 am
Portfolio Pulse from Benzinga Newsdesk
July 31, 2024 | 8:05 pm
Portfolio Pulse from Benzinga Newsdesk
July 08, 2024 | 11:55 am
Portfolio Pulse from Benzinga Newsdesk
July 08, 2024 | 11:35 am
Portfolio Pulse from Benzinga Newsdesk
July 08, 2024 | 11:27 am
Portfolio Pulse from Avi Kapoor
June 04, 2024 | 4:54 pm
Portfolio Pulse from Avi Kapoor
May 28, 2024 | 5:24 pm
Portfolio Pulse from Benzinga Newsdesk
May 15, 2024 | 5:22 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.